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Abstract
The 13th workshop of the European Bone Marrow Working 
Group in Utrecht, The Netherlands, was devoted to studying 
myelodysplastic syndromes (MDS) and their boundaries. The 
panel received 44 cases submitted to the 3 invited catego-
ries, which included: reactive cytopenias with dysplasia, id-
iopathic cytopenia of undetermined significance, clonal 
haematopoiesis of indeterminate potential, idiopathic dys-
plasia of uncertain significance and overt MDS. For this sum-
mary, we have selected 17 cases that highlight difficulties in 
separating true MDS from other causes of cytopenia and the 
intricate relationship between clonal haematopoiesis and 
true MDS. In addition, cases of overt MDS with challenging 
features were also selected. All cases were stained for p53 
expression. Using instructive submitted cases we discuss the 
following: (1) cytopenia with clonal haematopoiesis not ful-
filling MDS criteria, (2) cytopenia and/or dysplasia with 
germline mutations and/or familial history suggesting an 
underlying gene defect, (3) MDS based on a recurrent chro-
mosomal abnormality and (4) overt MDS with diagnostic dif-
ficulties due to concurrent treatment or disease. The lively 
discussion in the open forum of the workshop illustrated the 
need for better integrative understanding of the evolution 
of acquired genetic abnormalities in haematopoiesis, and 
the challenge of diagnosing true MDS in cytopenic patients 
with genetic abnormalities, either germline or acquired.
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Introduction
The diagnostic evaluation of patients with cytopenia 
requires the combination of clinical, laboratory and/or 
genetic data. Dysplasia in at least one haematopoietic 
cell line is mandatory for a diagnosis of myelodysplastic 
syndrome (MDS) [1]. The current work-up of cytopenic 
patients includes cytogenetic and often molecular ge-
netic testing to help establish clonality and to provide 
prognostic information if abnormal. A relatively large 
number of patients are detected with genetic alterations 
in the blood or bone marrow, otherwise lacking suffi-
cient criteria for the diagnosis of MDS. The designation 
“clonal cytopenia of undetermined significance” (CCUS) 
has been proposed for such instances [2]. Diagnostic cri-
teria of CCUS are discussed in this issue of Pathobiology 
[3]. The true risk of developing overt MDS in CCUS, 
depending on the involved gene and the type of genetic 
alteration, is still under investigation [4, 5]. In addition, 
some cytogenetic aberrations are considered to be diag-
nostic of MDS, even in the absence of sufficient dyspla-
sia to diagnose MDS on morphologic grounds. These 
aberrations include monosomy 7 or 13, loss of 5q and 
balanced translocation of chromosome 3, among others 
[1].
Genetic analysis of patients with suspicion of MDS 
can also reveal an underlying germline genetic defect 
predisposing them to develop a myeloid neoplasm. Al-
though patients with germline mutations can present 
with clinical symptoms or develop an overt myeloid neo-
plasm at any age, most patients present in childhood, 
often in the context of a specific clinical syndrome. Such 
genes include TERC [6] and GATA2 [7] that are now 
recognized in the group of genetic abnormalities predis-
posing to myeloid neoplasms in the updated World 
Health Organization (WHO) classification [8]. The gen-
eral diagnostic criteria of MDS also apply to these cases, 
but establishing a diagnosis of overt MDS can be chal-
lenging in cases with congenital dysplasia or in cases 
characterized by an evidence of bone marrow failure as-
sociated with a hypocellular bone marrow. It is also im-
portant to note that even in the context of overt dysplasia 
in a cytopenic patient, the diagnosis of MDS can be dif-
ficult because of cytotoxic treatment or concurrent dis-
eases that can induce cytopenia or dysplasia or mask an 
underlying MDS.
The 13th workshop of the European Bone Mar-
row  Working Group (EBMWG), held in Utrecht, The 
 Netherlands, invited submission of cases on 3 topics (1) 
reactive cytopenia and dysplasia, (2) clonal haematopoi-
esis of indeterminate potential (CHIP), idiopathic cyto-
penia of undetermined significance (ICUS) and idiopath-
ic dysplasia of unknown significance (IDUS), and (3) 
overt MDS. In total, 44 cases were received. Immunohis-
tochemical staining for p53 using the DO-7 antibody was 
performed on trephine biopsies of all workshop cases 
(Table 1).
For this summary, we made a selection of cases that did 
not completely fulfil clinical, morphological and/or ge-
netic features of MDS as well as cases of overt MDS with 
challenging features (Table 1). They are discussed below, 
grouped in the following categories: (1) cytopenia with 
clonal haematopoiesis not fulfilling MDS criteria, (2) cy-
topenia and/or dysplasia with germline mutations and/or 
family history suggesting an underlying gene defect, (3) 
MDS based on a recurrent chromosomal abnormality 
and (4) overt MDS with diagnostic difficulties due to a 
concurrent treatment or disease. Each category starts 
with brief case descriptions followed by a more extensive 
discussion, including the take-home messages for the 
practical diagnostic approach to such cases.
Patients and Results
Cytopenia with Clonal Haematopoiesis Not 
Fulfilling MDS Criteria
Case 1: Panel Diagnosis: CCUS (Differential Diagnosis of 
MDS with Single Lineage Dysplasia [MDS-SLD])
A 50-year-old man, otherwise healthy, had been followed for 
neutropenia and thrombocytopenia for 15 years prior to the 
bone  marrow biopsy (BMB). The normocellular bone marrow 
showed  left-shifted erythropoiesis with occasional megaloblas-
tic  changes  and rare hypolobated micromegakaryocytes (< 10%) 
without a  blast increase. The cytogenetic studies revealed 45,X, 
–Y[6]/47,XY,+8[4]/46,XY[15], and a next-generation sequencing 
(NGS) myeloid panel identified a mutation of ZRSR2 (variant al-
lele frequency [VAF] 77%). 
Case 2: Panel Diagnosis: CCUS with Later Progression 
to Overt MDS-SLD; Plasma Cell Neoplasm (Monoclonal 
Gammopathy of Undetermined Significance that Progressed 
to Smouldering Plasma Cell Myeloma)
A 68-year-old man was diagnosed with macrocytic anaemia, 
mild thrombocytopenia and monoclonal gammopathy of unde-
termined significance (MGUS; IgG lambda 0.4 g/L) after a 
2-month period of B-symptoms. BMB displayed subtle dysplasia 
in maturing granulocytes, megaloblastic erythropoiesis, occasion-
al hypolobated megakaryocytes, and occasional clusters of lamb-
da-restricted atypical plasma cells (< 5% of all cells; Fig. 1a). The 
karyotype was normal and morphologic features were insufficient 
for MDS, but pathogenic mutations in ASXL1, EZH2, SETBP 
(VAF 34–37%), and TET2 (VAF 72%) were identified. The diag-
nosis of CCUS and plasma cell neoplasm, MGUS, was made. A 
follow-up BMB after 6 months showed a hypercellular marrow 
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with dysplastic, hypolobated megakaryocytes and an increased 
plasma cell population (10%; Fig. 1b). The mutation results were 
unchanged. 
Case 3: Panel Diagnosis: Hypocellular Marrow with 
Paroxysmal Nocturnal Haemoglobinuria-Clone and CCUS, 
Suggestive of Evolving Aplastic Anaemia
A 69-year-old woman with pancytopenia and low reticulocyte 
count showed a hypocellular marrow with decreased myeloid and 
erythroid cells with full maturation, no dysplasia, and only very 
scarce, occasionally dysplastic megakaryocytes (Fig. 1c). Flow cy-
tometry revealed a paroxysmal nocturnal haemoglobinuria (PNH)-
clone (2% of red blood cells, 11% of neutrophils). The karyotype 
was normal. NGS showed a DNMT3A mutation (VAF 22%). 
Case 4: Panel Diagnosis: Hypercellular Bone Marrow on 
Active Therapy, Suspicious but Not Diagnostic of MDS or 
MDS/MPN (Myeloproliferative Neoplasia), Recommend 
Repeat Bone Marrow after Stopping Methotrexate
A 67-year-old man with rheumatoid arthritis treated with 
methotrexate and prednisone for several years and a prior his-
tory of low-dose radiotherapy to the orbit because of conjunctival 
marginal zone lymphoma showed persistent normocytic anae-
mia, thrombocytopenia and neutrophilia for 2 years, but no 
monocytosis. The bone marrow was hypercellular with megalo-
blastic erythropoiesis and normal myeloid maturation. Mega-
karyocytes were adequate in number and highly variable in ap-
pearance, although < 10% of cells were dysplastic (Fig. 1d). The 
karyotype was 47,XY,+8[14/20]. NGS identified pathogenic mu-
tations of SRSF2 (VAF 47%) and IDH2 (VAF 46%). Testing for 
JAK2, MPL, and CALR mutations and BCR-ABL1 rearrange-
ment was negative. 
All the above cases presented with cytopenia and one or more 
pathogenic MDS-type mutations, but they lacked significant dys-
plasia or a diagnostic clonal cytogenetic abnormality, required for a 
diagnosis of MDS [1]. Cases 1 and 4 showed trisomy 8, which is not 
sufficient to diagnose MDS. In addition, all had interfering factors 
that would discourage rendering an MDS diagnosis. These were a 
very long history of clinically stable cytopenias (15 years, case 1), 
drugs known to cause cytopenia/dysplasia or neutrophilia (metho-
trexate and prednisone, respectively, case 4, see also “Overt Myelo-
dysplastic Syndrome with Diagnostic Difficulties Due to Concur-
rent Treatment or Diseases”), aplastic anaemia (AA) with a PNH-
clone (case 3) or a concurrent plasma cell neoplasm (case 2).
In suspected MDS, an abnormal flow cytometric immunophe-
notype can help to identify low-grade MDS cases (e.g., reflected by 
the so-called Ogata score [9]) and to predict progression to overt 
MDS [10]. In CCUS, several additional clues may indicate an in-
creased risk to develop MDS. These include the presence of 2 or 
more pathogenic mutations, a large size of the mutant clone as in-
dicated by a high VAF and certain specific mutations or their com-
binations [5, 11, 12]. The “high-risk” myeloid gene mutation pat-
tern in CCUS includes spliceosome gene mutations (especially 
SF3B1, but also SRSF2, U2AF1, ZRSR2); or a DNMT3A, TET2 or 
ASXL1 mutation in combination with any other mutation (all mu-
tations should be at > 10% VAF) [5, 11]. In contrast, isolated muta-
tions in TET2, DNMT3A and ASXL1, which can be seen in healthy 
elderly people without cytopenia (CHIP), carry a lower risk of a 
subsequent myeloid neoplasm. According to its working defini-
tion, CHIP cases do not exhibit morphological evidence of a hae-Ca
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matological neoplasm, they do not meet diagnostic criteria for 
PNH, MGUS or monoclonal B-cell lymphocytosis, and they con-
tain somatic mutations associated with haematological neoplasia 
at a VAF of at least 2% [2, 5, 13]. Case 2 illustrates that the presence 
of a pathogenic mutation combination (TET2 and ASXL) at a high 
VAF permits early identification of evolving MDS and helps to rule 
out benign cytopenia (“reactive” dysplasia) even in the setting of 
concomitant plasma cell neoplasm.
The clinical significance of isolated mutations in the most com-
monly mutated spliceosome genes remains unknown. An isolated 
ZRSR2 mutation was found in case 1 that was characterized clini-
cally by prolonged and stable neutropenia and thrombocytopenia. 
Fleischman et al. recently reported 2 CCUS cases with an isolated 
ZRSR2 mutation and refractory macrocytic anaemia with a clinical 
course similar to case 1 [14].
Case 4 shows a combination of iatrogenic factors (chronic pred-
nisone and methotrexate treatment for rheumatoid arthritis) that 
can together account for the normocytic anaemia, thrombocytope-
nia, neutrophilia and dysplasia (as further described below in 
“Overt myelodysplastic Syndrome with diagnostic Difficulties Due 
to Concurrent Treatment or Diseases”). The additional trisomy 8 
and mutations in the spliceosome gene SRSF2 and the DNA meth-
ylation gene IDH2, however, suggest an underlying MDS, although 
dysplasia criteria were not yet fully met. The possibility of a thera-
py-related myeloid neoplasm associated with a previous short, low-
dose radiotherapy focused on the orbit appeared unlikely, despite 
the fact that the WHO classification criteria for therapy-related my-
eloid neoplasms do not take into account the radiation dosage or 
degree of bone marrow exposure, and thus criteria for therapy-re-
lated MDS might be formally met in this case [15].
a b
c d
Fig. 1. Case 2: clonal cytopenia of undetermined significance 
(CCUS) and monoclonal gammopathy of undetermined signifi-
cance (MGUS). a The bone marrow biopsy (BMB) shows mostly 
normal megakaryocytes (right and left, H&E). b The same case, 6 
months later with progression to MDS-SLD (and smoldering plas-
ma cell myeloma). Dysplastic, small hypolobated megakaryocytes 
are present on the BMB (H&E), as confirmed by CD42b IHC (in-
set). c Case 3: Hypocellular marrow with PNH clone and CCUS, 
suggestive of evolving aplastic anaemia (AA). The trephine biopsy 
is markedly hypocellular (left). On higher magnification, the cel-
lularity is mostly maturing erythroid and myeloid elements, with 
very scarce megakaryocytes (H&E). d Case 4: Hypercellular bone 
marrow on active therapy, suspicious but not diagnostic of MDS 
or MDS/MPN. The aspirate smear shows megaloblastic erythroid 
and normal myeloid maturation; rare dysplastic erythroid cells 
(<10%) are appreciated (wright Giemsa). 
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It has to be stressed that various parts of the findings have to be 
weighed and interpreted in an appropriate context of other clinical 
and laboratory findings for a reliable diagnosis. Solitary MDS-type 
mutations or chromosomal abnormalities in a cytopenic patient 
may sometimes represent CHIP [2] combined with reactive cyto-
penia. Significant (> 10%) dysplasia may occur in non-MDS condi-
tions too, as discussed below in “Overt Myelodysplastic Syndrome 
with Diagnostic Difficulties Due to Concurrent Treatment or Dis-
eases”. Even if mutations and dysplasia are present, other possible 
causes of cytopenia must always be excluded. Repeated bone mar-
row sampling may be needed to establish the diagnosis, and, in 
some cases, to identify the progression to overt MDS.
MDS-type mutations indicative of clonal haematopoiesis oc-
cur frequently in AA as well; the majority of patients with AA 
have evidence of clonal haematopoiesis [16, 17]. An overlap of 
certain immunomorphologic and genetic features of AA, MDS 
and PNH is documented in case 3 combining CCUS with a 
 DNMT3A mutation, a PNH clone and a hypocellular bone mar-
row, suggestive of evolving AA. DNMT3A mutations can be ob-
served in MDS (5–13% of cases), AA (6–12%) [17], and acute 
myeloid leukaemia (AML; 22%) [18], but also in otherwise 
healthy people (2% of persons over 70 years) [16, 17, 19]. The 
pathophysiology of PNH clone expansion in AA or MDS is not 
well understood; nevertheless, small PNH clones may be found 
in 20–35% of patients with MDS, and 30–50% of cases of AA may 
evolve into classic PNH [20, 21], and/or eventually into MDS 
with or without subsequent AML [22]. These diagnostic chal-
lenges underline the role of bone marrow histology with a panel 
of immunohistochemical markers in the work-up of unclear cy-
topenias with/without dysplasia. Immunohistochemical staining 
for p53 may provide additional information to help differentiate 
hypoplastic MDS from AA [23, 24]. Strong nuclear p53 staining 
has in previous studies been shown to be useful as both a diag-
nostic and a prognostic marker [25, 26], and may be associated 
with an underlying TP53 mutation [27]. All cases submitted to 
the bone marrow workshop were stained for p53 using clone 
DO-7 (DAKO) on unstained bone marrow slides (results in Ta-
ble 1). Only one of the cases that did not fulfill MDS criteria 
showed bone marrow cells with strong nuclear p53 staining (case 
6 in “Cytopenia and/or Dysplasia with Germline Mutations and/
or Familial History Suggesting an Underlying Gene Defect”).
Another interesting feature illustrated by cases 4 and 17 (“Overt 
Myelodysplastic Syndrome with diagnostic Difficulties Due to 
Concurrent Treatment or Diseases”) is the possible relationship 
between pre-existing autoimmune disease (rheumatoid arthritis 
and autoimmune cytopenia) and the development of MDS. A re-
cent review summarizes the evidence for immune-mediated 
pathophysiological mechanisms shared by autoimmune cytope-
nias, ICUS, IDUS and low-risk MDS, including cytokine dysregu-
lation, increased apoptosis and the role of toll-like receptors [28].
Cytopenia and/or Dysplasia with Germline Mutations and/or 
Familial History Suggesting an Underlying Gene Defect
Case 5: Panel Diagnosis: Germline GATA2 Mutation 
Predisposition Syndrome (with Questionable Progression 
to MDS-SLD)
A now 15-year-old male had experienced recurrent streptococ-
cal infections and bacteremias, and human papillomavirus-driven 
warts on the extremities from the age of 5 onwards. Lymphangiec-
tasia in the right thigh region led to recurrent scrotal and penile 
lymphedema. Immunodeficiency testing revealed B lymphopenia 
without hypogammaglobulinemia, an inverted CD4/CD8 ratio, 
and slight neutropenia and monocytopenia. His bone marrow was 
hypocellular (10–20%) with decrease of all cell lines, occasional 
dysplastic megakaryocytes but no blast increase. A GATA2 muta-
tion was detected in his blood and the bone marrow showed an 
additional ASXL1 mutation (VAF 11%). 
Case 6: Panel Diagnosis: Bone Marrow Failure in a Patient 
with USB1 Gene Mutation
A 17-year-old male patient with neutropenia and lymphopenia 
was born in a consanguine family. He was affected by frequent in-
fections (that required hospitalization) in his childhood and had 
remarkably dry skin with increasing, itchy hyper- and hypopig-
mented macules and patches all over his body (Fig. 2a). The skin 
on his palms and feet was thickened, his nails were hard and mal-
formed (Fig. 2a insert), one toenail was missing, his fingers were 
clubbed and he had an epicanthus. The bone marrow was slightly 
hypocellular for his age with hypolobated megakaryocytes and eo-
sinophilia (Fig. 2b). The aspirate smear showed neutrophils with 
hyposegmented or clumpy nuclei, pseudo-Pelger forms, large 
metamyelocytes, intercytoplasmic bridging and occasional mega-
loblastic changes in the erythroid precursors (Fig. 2c). On immu-
nohistochemistry (IHC), blasts were slightly increased (3–4%), 
without clustering. Approximately 10% of myelopoietic cells 
strongly expressed p53 (Fig. 2d), and on flow cytometry some ma-
turing granulocytic cells showed aberrant expression of CD56 (a 
non-specific finding, which in isolation does not imply a diagnosis 
of MDS). A genodermatosis was suspected and Fanconi anaemia 
was excluded by chromosome breakage studies. Panel sequencing 
revealed a homozygous mutation of the USB1 gene, confirming 
the diagnosis of poikiloderma with neutropenia (Clericuzio type), 
a rare autosomal-recessive genodermatosis with associated bone 
marrow failure, predisposing to malignancy. 
Case 7: Panel Diagnosis: Hereditary Bone Marrow 
Failure Syndrome with Dysplastic Features, Probably 
Autosomal Recessive
A 18-month-old boy with physical dysmorphism (long ears, 
short philtrum) had siblings’ history of transfusions and family 
members with a history of skin cancer. He was born in a consan-
guine family and presented with pancytopenia requiring transfu-
sions early after birth. He showed a hypochromic microcytic anae-
mia, thrombocytopenia and neutropenia with dysplastic hyperseg-
mented neutrophils. His karyotype was normal and t(8; 21) and 
inversion 16 were excluded. The bone marrow was slightly hypo-
cellular for his age with a reduction of the megakaryopoiesis with 
some pyknotic forms, megaloblastic erythropoiesis and consider-
able dysmaturation of the myelopoiesis. There was also siderosis. 
The child died 3 weeks later under supportive treatment without 
growth factors. No mutation screening was performed. 
Case 8: Panel Diagnosis: Refractory Cytopenia of Childhood
A 3-year-old girl was referred with extensive bruising commenc-
ing 3 months after birth. She showed pancytopenia, lymphocytosis 
and monocytosis with increased foetal haemoglobin (5.5%). The 
bone marrow was severely hypocellular (10–30% cellularity) with 
dyserythropoiesis and dysplastic megakaryocytes, while granulopoi-
esis was markedly decreased and left shifted. Blasts were not in-
creased. Fluorescence in situ hybridization (FISH) of the bone mar-
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row showed monosomy 7 in 59% of the cells. A 30 myeloid gene NGS 
panel showed no mutations. The family history was not available. 
Children and young adolescents that present with bone mar-
row failure, as in the above cases, require an integrative diagnostic 
approach, taking into consideration age, detailed clinical and fam-
ily history, physical examination, and peripheral blood smear and 
bone marrow examination to narrow down the number of spe-
cific differential diagnoses and guide additional genetic studies to 
establish a diagnosis.
Of the major inherited bone marrow failure syndromes, Fan-
coni anaemia and dyskeratosis congenita have an especially high 
risk of developing MDS or AML, while the risk is lower in Dia-
mond-Blackfan anaemia and Shwachman-Diamond syndrome 
[29]. Long-term granulocyte colony stimulating factor (G-CSF) 
therapy in severe congenital neutropenia increases MDS and AML 
risk to a similar level as in Fanconi anaemia [30].
Several other predisposing disorders with germline mutations 
have been acknowledged in the revised WHO classification [8]. 
Among these is GATA2 deficiency due to a germline mutation that 
has a high risk of progression to MDS at an early age. The clinical 
presentation is quite diverse, ranging from lymphedema, severe 
mycobacterial or viral infections to AA [31], as in case 5. Only 20% 
of the patients initially present with a myeloid neoplasm, but most 
develop MDS or AML in the years after diagnosis [31].
Monosomy 7 as in case 8 is a frequent acquired aberration in 
both paediatric and adult MDS, either alone or in combination 
with other generic alterations [32]. In adults it is commonly associ-
ated with therapy-related myeloid neoplasms following chemo-
therapy with alkylating agents or occupational exposure to chem-
ical toxins. Monosomy 7 has an adverse prognostic impact in both 
children and adults, depending on the presence of additional ge-
netic abnormalities [32–34]. It is the most frequently acquired ab-
normality in MDS/AML associated with inherited bone marrow 
failure syndromes and is associated with a germline GATA2 muta-
tion in 37% of cases [35]. The incidence of monosomy 7 in refrac-
tory cytopenia of childhood is up to 49% of cases [33]. The early 
a b
d e
c
Fig. 2. Case 6: 17-year-old male patient affected by poikiloderma 
with neutropenia due to bi-allelic USB1 germline mutation. a Clin-
ical image with itchy hyper- and hypopigmented macules and 
patches all over the body and (insert) onychodystrophy. b Bone 
marrow biopsy (BMB) with slight hypocellularity and eosinophil-
ia (H&E). c Bone marrow aspirate smear with dysgranulopoiesis 
(hypogranulated neutrophils with hyposegmented and clumpy 
nuclei, pseudo-Pelger forms, large metamyelocytes, intercytoplas-
mic bridging) and occasional megaloblastic changes in the ery-
throid precursors (wright Giemsa). d p53 (brown)/myeloperoxi-
dase (red) and e p53 (brown)/CD3 (red) double-stainings showing 
that approximately 10% of the myelopoietic cells abnormally co-
express p53, while T-cells remain p53 negative, in line with the 
severe morphologic dysgranulopoiesis. 
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onset of clinical symptoms in case 8 suggests a prodromal phase 
before overt refractory cytopenia of childhood at age 3. In similar 
cases, an undiscovered hereditary predisposition should be care-
fully investigated by dedicated gene screening. Another special 
condition that should be considered is familial monosomy 7, typi-
cally characterized by early-childhood onset and bone marrow in-
sufficiency in at least one affected family member, and association 
with increased risk for MDS or AML [36]. Most patients present 
with evidence of bone marrow insufficiency such as petechiae, easy 
bruising and/or anaemia as in case 8. The monosomy 7 is not pres-
ent at birth but is acquired within haematopoietic cells due to an 
inherited genetic predisposition that leads to mosaicism of chro-
mosome 7 in peripheral blood and/or bone marrow. Germline 
SAMD9 and SAMD9L variants have been recently linked to famil-
ial and sporadic cases of paediatric MDS with monosomy 7 [37]. 
Abnormal haematologic findings and mosaic monosomy 7 can al-
ready appear in young children with familial monosomy 7. The 
prognosis after occurrence of the monosomy is poor, with rapid 
progression to MDS/AML [36].
Non-cyclic cytopenias in patients with congenital malforma-
tions, dysmorphic features, nail dystrophies, café-au-lait spots, hy-
popigmentation or premature greying are suspicious of genoder-
matoses and require further genetic testing. Diagnoses that have to 
be excluded are dyskeratosis congenita and Fanconi anaemia. Poi-
kiloderma with neutropenia caused by bi-allelic USB1 germline 
mutations as in case 6 can overlap clinically with dyskeratosis con-
genita and shares the risk of developing myeloid neoplasia [38, 39]. 
The derived USB1 protein has a role in RNA processing. Acquired 
mutations in USB1 have been observed in a small subset (2/140 
tested cases) of haematopoietic malignancies, supporting the role 
of the USB1 gene in the development of myeloid neoplasms [40].
MDS Based on a Recurrent Chromosomal Abnormality
Case 9: Panel Diagnosis: MDS-Unclassifiable (Based on 
Cytogenetics in the Absence of Sufficient Dysplasia)
Macrocytic anaemia and thrombocytopenia were found in a 
76-year-old male in the background of a hypercellular bone mar-
row with decreased iron stores, mild dyserythropoiesis and left-
shifted myeloid maturation without increased blasts or significant 
dysmegakaryopoiesis (Fig. 3a), except for an occasional non-lobat-
ed megakaryocyte (Fig. 3b). The karyotype showed 46,XY,inv(3)
(q21q26.2)[3]. GATA2, MECOM involvement was confirmed by 
FISH (Fig. 3b). No follow-up data was available. 
Case 10: Panel Diagnosis: MDS-Unclassifiable 
(Based on Cytogenetics)
A 66-year-old female presented with persistent pancytopenia 
and a normocellular bone marrow with an increase in erythroid 
precursors but no dysplasia or increase of myeloid blasts. Initially 
an ETV6 mutation with unknown significance but normal karyo-
type was found. A repeated biopsy after 6 months showed addi-
tional del(13)(q12q22) in 2/20 metaphases. The patient was stable 
for 2 years with transfusions and antithymocyte globulin/ciclospo-
rin/prednisone treatment. 
Case 11: Panel Diagnosis: MDS-Unclassifiable 
(Based on Cytogenetics)
A 48-year-old female had AA with pancytopenia and a hypo-
plastic bone marrow (15% cellularity) without dysplasia and with a 
normal karyotype. After 6 months of treatment with ciclosporin, 
a
b
c
Fig. 3. Case 9: 76-year-old male with no past medical history who 
presented with macrocytic anaemia and thrombocytopenia. a Hy-
percellular BMB without significant dysplasia (H&E). b A single 
non-lobated megakaryocyte. Usually (but not in this case) non-
lobated and bi-lobated megakaryocytes are easily identifiable in 
cases of myeloid neoplasms associated with inv(3) (q21.3;q26.2) or 
with t(3; 3) (q21.3;q26.2). c FISH shows several normal cells (2 red 
and 2 green spots) and a rearrangement of the RPN1 enhancer 
(green spot) to the MECOM gene (red spot) on chromosome 3, 
indicative of inversion 3. 
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the clinical and laboratory parameters did not change. Under a 
temporary gluten-free diet and G-CSF treatment, transfusion need 
decreased and the bone marrow became hypercellular due to an 
increase of erythroid precursors. Megakaryocytes and myeloid pre-
cursors were decreased. At this stage, monosomy of chromosome 
7 was found, while significant dysplasia was still lacking.  Danazol 
was added to the G-CSF support and the patient no longer required 
transfusions for a follow-up of 16 months since presentation. 
The presence of specific chromosomal abnormalities is suffi-
cient for a diagnosis of MDS-unclassifiable, in patients with refrac-
tory, unexplained cytopenia, even if dysplasia and blast increase 
are absent [41]. These include (partial) loss of chromosomes 7 
(case 11) or 13 (case 10), and inversion of chromosome 3, that is, 
inv(3)(q21.3;q26.2), or balanced translocation t(3; 3)(q21.3;q26.2) 
(case 9). The latter cytogenetic abnormalities are often associated 
with the presence of small megakaryocytes with non-lobated or bi-
lobated nuclei (Fig. 3b). In contrast, workshop case 9, that seems 
to represent an early clinical manifestation of the disease, lacks 
evidence of significant morphologic dysplasia.
The aggressive clinical course seen in patients with myeloid 
neoplasm with deregulation of MECOM and GATA2 is unrelated 
to the number of blasts, that is, of the subclassification of the case 
as MDS or AML. Prognosis is even worse for cases with a complex 
or monosomal karyotype [42]. 
Deletion of 13q is found with a low frequency in AA and MDS, 
especially in cases lacking clear dysplasia as in case 10 [43, 44]. As-
sociated characteristics are a good response to immunosuppres-
sive therapy, frequent PNH clones, and a relatively low risk of pro-
gression to high-grade MDS or AML. This suggests an autoim-
mune/cytokine role in the disease pathogenesis [41].
Several other chromosomal abnormalities (loss of chromo-
some Y), trisomy 8 and del(20q) and MDS-related gene mutations 
(e.g. DNMT3A, TET2, ASXL1) are not sufficient to diagnose MDS, 
since they can be found as acquired clonal events in the haemato-
poietic cells of healthy people and patients without myeloid neo-
plasms [45, 46]. Since these mutations can drive clonal expansion 
of haematopoiesis, they are considered within the spectrum of 
CHIP, but they appear to show a relatively low risk of progression 
towards myeloid neoplasm [2].
Pathogenic germline mutations (including RUNX1) require a 
different approach as they can predispose to myeloid neoplasms, 
but by themselves are not sufficient to render a diagnosis of MDS, 
as described in “Cytopenia and/or Dysplasia with Germline Muta-
tions and/or Familial History Suggesting an Underlying Gene 
 Defect”. 
Overt Myelodysplastic Syndrome with Diagnostic Difficulties 
Due to Concurrent Treatment or Diseases
Case 12: Panel Diagnosis: Therapy-Related Myeloid 
Neoplasm (Therapy-Related MDS). Note: Subsequent 
Progression to Therapy-Related AML
A 28-year-old female was admitted with vomiting, petechial 
rash and severe pancytopenia requiring transfusions, and was di-
agnosed with AA with a normal karyotype. Five months later, she 
collapsed and two partly empty bottles of melphalan tablets were 
found besides her. She admitted ingestion of melphalan prior to 
the first admission. Because of persisting thrombocytopenia after 
10 months, a BMB was performed and showed reduced megakary-
ocytes. Almost 2 years after the first admission, an additional BMB 
following progressive pancytopenia revealed a cellular marrow 
with myeloid and erythroid dysplasia, left-shifted, erythroid ex-
pansion and a reduced number of megakaryocytes, which were 
dysplastic. Interestingly, p53 staining revealed > 5% cells with 
strong nuclear staining, while the initial (hypoplastic) bone mar-
row sample stained negative, indicating clonal evolution. The 
karyotype showed many abnormalities, including deletions, dupli-
cations and unbalanced translocations. With FISH, an additional 
copy of MECOM was seen. A diagnosis of a therapy-related my-
eloid neoplasm was made. During the work-up for allogeneic hae-
matopoietic stem cell transplantation (HSCT), she progressed to 
full blown AML with a monosomal karyotype, including mono-
somy 7. The AML was refractory to chemotherapy and she died 
within 3 months from pneumocystis pneumonia. 
Case 13: Panel Diagnosis: MDS with Isolated del(5q)
Incidentally, macrocytic anaemia and leucopenia were discov-
ered in a 75-year-old male and were attributed to an underlying 
atrophic gastritis with very low vitamin B12 levels. Vitamin B12 
therapy did not correct the blood values and he developed fatigue, 
dyspnea and transfusion dependency. A BMB showed a hypercel-
lular marrow with increased, megaloblastic erythropoiesis and in-
creased, frequently monolobated megakaryocytes but no blast in-
crease. P53 staining revealed the presence of strongly positive 
staining precursor cells at a low frequency (< 5%). The karyotype 
showed loss of chromosome 5(q13q32–34), and FISH confirmed 
loss of EGR1 and PDGFRB genes on 5q, leading to a diagnosis of 
MDS with isolated del(5q). NGS did not detect any mutations of 
TP53, but of several other genes (ATM VAF 17%, ASXL1 VAF 
29%, JAK2 VAF 9%). The patient improved markedly on lenalid-
omide with normal blood values and did not require transfusion. 
Case 14: Panel Diagnosis: MDS Not Further Classifiable (no 
Excess Blasts). Note: Presence of Erythroblastopenia and 
Neutrophil-Rich Bone Marrow after Infection
An 88-year-old-male on antibiotics for a foot infection was 
seen with shortness of breath, fatigue and bilateral lower extrem-
ity oedema. Blood values showed leukocytosis (19 × 109/L), anae-
mia and low platelets. Abdominal ultrasound showed a perihe-
patic lesion suspicious for an abscess, which was attributed to re-
cent trauma. A BMB was 90% cellular with increased left-shifted 
granulopoiesis and 2% CD34+/CD117+ blasts. P53 staining 
showed 2% cells with strong nuclear staining. Erythropoiesis and 
megakaryopoiesis were markedly decreased with a few small, hy-
polobated megakaryocytes. Immunophenotyping by flow cytom-
etry showed abnormal myeloid maturation, including CD56 ex-
pression on granulocytes and monocytes. FISH and karyotyping 
were normal. No mutations in MPN-related genes were detected, 
but mutations in RUNX1 (VAF 47%) and TET2 (VAF 46%) were 
present. The white blood cell count normalized on follow-up, 
while anaemia and thrombocytopenia persisted. 
Case 15: Panel Diagnosis: MDS-EB-2. Note: Erythroid 
Proliferation Post Azacitidine Treatment
A BMB was performed in an 80-year-old previously healthy 
male because of normocytic anaemia and mild thrombocytopenia. 
The marrow was hypercellular with dyserythropoiesis, left-shifted 
hypogranular myelopoiesis, monolobated megakaryocytes, 5–10% 
CD34 positive blasts and > 20% cells with strong p53 staining, in-
cluding megakaryocytes (Fig. 4a). A repeated aspirate showed 15% 
blasts. FISH revealed loss of chromosome 5q, monosomy 7 and an 
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Fig. 4. Case 15: Bone marrow biopsy of an 
anaemic 80-year-old male. a P53 immuno-
histochemical staining shows an increased 
number of progenitor cells with strong nu-
clear staining. b, c Erythroid proliferation 
with dysplastic features and the dysmega-
karyopoiesis (H&E). d Increased megaloid 
erythropoiesis is illustrated by glycophorin 
A. e CD61 highlighting the small dysplastic 
megakaryocytes. f, g Case 16. Acquired al-
pha-thalassemia and MDS in a 58-year-old 
male with microcytosis and anisopoikilo-
cytosis. f Blood smear with haemoglobin H 
inclusions in the erythrocytes (wright Gi-
emsa). g A hypocellular bone marrow bi-
opsy with striking dysmegakaryopoiesis 
(H&E).
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additional copy of MECOM in about 50% of the cells. MDS-EB-2 
was diagnosed and azacitidine treatment was started. Although 
blood values temporarily normalized, after 6 cycles the clinical con-
dition deteriorated to transfusion-dependent pancytopenia with-
out circulating blasts. A new BMB showed a somewhat less cellular 
marrow with an increased, markedly anaplastic erythropoiesis with 
giant forms and prominent bright eosinophilic nucleoli and vari-
able CD117 expression (Fig. 4b–d), accounting for up to 40% of all 
nucleated cells. There was profound dysmegakaryopoiesis, which 
included both micromegakaryocytes and small dysplastic forms 
with hypolobated nuclei (Fig. 4e). The aspirate showed trilineage 
dysplasia and 5% myeloid blasts. FISH remained unchanged with 
loss of chromosome 5q, monosomy 7 and an additional copy of 
MECOM. Azacitidine was discontinued. The patient remained se-
verely pancytopenic and passed away 2 months later. 
Case 16: Panel Diagnosis: MDS with Multilineage Dysplasia 
(MDS-MLD; Hypoplastic)
An anaemic 58 year-old-male presented with microcytosis and 
marked anisopoikilocytosis, including target cells, elliptocytes, 
acanthocytes and haemoglobin H (HbH) inclusions (haemoglobu-
lin electrophoresis revealed 9.9% variant HbH; Fig. 4f). His bone 
marrow was hypocellular with dysmegakaryopoiesis, dyserythro-
poiesis and mild dysgranulopoiesis but no blast increase (Fig. 4g); 
p53 staining was negative. Further genetic analysis showed del(7)
(q22q36) in 2 out of 20 metaphases and pathogenic mutations in 
ASXL1, U2AF1 and ATRX. The latter confirmed the diagnosis of 
acquired alpha-thalassemia in the context of MDS-MLD. In addi-
tion, a clonal T-cell population was detected in the bone marrow 
using IHC and molecular analysis. The patient underwent alloge-
neic HSCT with initial engraftment. Six months post-HSCT de-
creased chimerism heralded a cytogenetic relapse in a markedly 
hypocellular bone marrow. 
Case 17: Panel Diagnosis: MDS-EB-1. Note: Left-Shifted 
Granulopoiesis after Steroids; Prior History of 
Autoimmune Cytopenia
Three years after the first discovery of mild pancytopenia at the 
time of diagnosis of breast carcinoma (radiation and hormonal 
therapy only), a 65-year-old female had a BMB for worsening pan-
cytopenia. The marrow was mildly hypercellular without dyspla-
sia. The karyotype was normal. She received steroids and several 
transfusions for presumed autoimmune cytopenia. Four years lat-
er, her pancytopenia worsened and she showed only a mild re-
sponse to steroids. The bone marrow was now hypercellular with 
markedly increased and left-shifted myelopoiesis with 5% blasts 
and 58% myelocytes and promyelocytes. Megakaryocytes were 
dysplastic. The karyotype remained normal, NGS showed SRSF2 
(VAF 56%), ASXL1 (VAF 51%) and 2 TET2 mutations (VAF 47 
and 49%). A subsequent BMB performed approximately 6 months 
later included the same mutations: RUNX1 (VAF 34%), SRSF2 
(VAF 60%), ASXL1 (VAF 41%), TET2 (VAF 43% for both vari-
ants). The decreased percentage in the VAFs in the second biopsy 
suggests that these were not germline mutations.
Coincidence of MDS with another disease or co-morbid condi-
tion can pose a diagnostic challenge. MDS can be erroneously dis-
regarded because of a concurrent disorder or treatment that seems 
to explain the cytopenia(s). Drugs in general can cause a wide 
range of haematologic abnormalities [47, 48]. Extreme myeloid 
hyperplasia, dysplastic features and/or left-shifted myelopoiesis 
with increase of blasts can result from severe infection (case 14), 
cytotoxic therapy as Melphalan (case 12), G-CSF treatment or 
trauma. Glucocorticoid treatment alone (cases 4 and 17) can cause 
neutrophilia and induce dysplastic changes in myeloid cells [49].
Marked erythroid hyperplasia with/without dysplasia can oc-
cur in severe blood loss, deficiencies of folic acid or vitamin B12 
(case 13), PNH, acquired α-thalassemia (case 16), azacitidine (case 
15) or erythropoietin treatment. Azacitidine is an anti-metabolite 
that inhibits DNA methylation and disrupts RNA metabolism and 
protein synthesis with a direct effect on erythroblast maturation 
[50].
Germline mutations in the ATRX gene induce a neurological 
syndrome, the so-called Alpha-Thalassemia, mental Retardation 
X-linked (ATRX) syndrome. Acquired inactivating ATRX muta-
tions do occasionally occur in the context of MDS, leading to mi-
crocytic anaemia, anisopoikilocytosis, and HbH inclusions as in 
case 16 [51]. Almost all reported patients are elderly males and the 
ATRX mutation does not seem to influence the chance of leukemic 
transformation.
Two of the cases in this category (cases 13 and 15) had loss of 
chromosome 5q. Both showed the characteristic non-lobated 
megakaryocytes of MDS with isolated del(5q), but this diagnosis is 
not applicable to case 15 due of the accompanying monosomy 7. 
Because of the adverse prognostic impact of monosomy 7, the 
presence of this additional abnormality excludes classification as 
MDS with isolated del(5q) that otherwise has a favourable out-
come and responds to lenalidomide [52]. TP53 mutations occur in 
MDS with del(5q) and, while they do not exclude this diagnosis, 
the presence of a mutation may be associated with resistance to 
lenalidomide. Thus, encountering such TP53 mutations, even at 
low VAF, in otherwise typical del(5q) MDS appears to indicate 
more aggressive disease that may warrant other therapeutic ap-
proaches [27]. In the revised WHO 2016 classification, immuno-
histochemical staining for p53 is recommended particularly for 
this subgroup of MDS [52]. However, we recommend p53 staining 
in the diagnostic work-up of any unclear cytopenia with/without 
dysplasia and in all MDS subtypes, both at diagnosis and during 
follow-up, since it may be helpful as a diagnostic and prognostic 
marker and may indicate disease progression (case 12). Strong nu-
clear p53 staining may indicate an underlying TP53 mutation; 
however, this should be confirmed by molecular analysis. The lack 
of immunohistochemical expression may in rare cases result from 
a nonsense mutation leading to formation of a truncated, non-
immunoreactive protein. However, p53 IHC detects a large frac-
tion of the TP53 mutations in MDS, which are predominantly mis-
sense mutations [53]. Finally, it should be emphasized that the type 
of fixation, decalcification procedures and antibody selection may 
impact staining results when studying p53 in tissue sections in 
MDS, as results may vary with different antibodies as shown in 
previous studies [24]. 
Conclusion
MDS is one of the most challenging areas of diagnos-
tic bone marrow pathology. While the disease is defined 
by the combination of cytopenia(s), dysplasia and clon-
al haematopoiesis, each of these features are not limited 
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to MDS. The 13th workshop of the EBMWG was de-
voted to the spectrum of benign simulators, borderline 
cases and overt MDS with unusual features. Here we 
have summarized a selection of the workshop cases il-
lustrating the following themes: CCUS not fulfilling 
MDS criteria, cytopenia and/or dysplasia with germline 
mutations and/or familial history suggesting an under-
lying gene defect, MDS-unclassifiable based on a recur-
rent chromosomal abnormality and overt MDS with di-
agnostic difficulties due to concurrent treatment or dis-
eases.
This workshop illustrates that integration of all data, 
including the knowledge of concurrent diseases and ther-
apy and the patient’s family history, as well as flow cytom-
etry and molecular genetic findings is of utmost impor-
tance to avoid the pitfalls of over- and underdiagnosing 
MDS.
Summary
The most important lessons learnt from the workshop are: 
In order to avoid overdiagnosis of MDS, be aware that: 
 − Significant (> 10%) dysplasia may occur in non-MDS condi-
tions. 
 − MDS-type mutations in a cytopenic patient can be seen in cas-
es of co-occurrence of CHIP and non-MDS cytopenia (CCUS).
 − Significant megakaryocyte dysplasia may be seen in germline 
mutation syndromes without MDS and can sometimes be in-
duced by drugs. 
In order to avoid underdiagnosing MDS, keep in mind that:
 − MDS morphologic features can be obscured by concurrent dis-
eases or treatment effects on the bone marrow, therefore, re-
peated bone marrow sampling may be necessary to establish 
the diagnosis. 
 − In the challenging setting of CCUS, it is most helpful to iden-
tify a “high-risk” myeloid gene mutation pattern. This helps to 
predict the cases that are probably “true” MDS precursors that 
will show progression, as illustrated by some of the workshop 
cases. 
 − Additional clues in CCUS that may indicate a “true” pre-MDS 
condition are flow cytometry abnormalities and mutations 
with high VAF.
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